Carcinogenesis, Vol. 24, No. 3, 461-467,
March 2003
© 2003 Oxford University Press
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION |
Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene–DNA adducts and tumor yield in mice
1 Department of Environmental Health Sciences, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, MD 21202, USA and
2 Center for TARA, Tsukuba University, Tsukuba 305, Japan
The cancer chemopreventive actions of oltipraz (4-methyl-5-[2-pyrazinyl]-1,2-dithiole-3-thione) have been primarily associated with the induction of phase 2 detoxifying enzymes through transcriptional activation of the antioxidant response element (ARE) in the promoter regions of these genes. The transcription factor Nrf2 has been shown to bind to and activate AREs. Previously, we demonstrated that nrf2-deficient mice had low basal expression of phase 2 enzymes and were substantially more susceptible to benzo[a]pyrene (B[a]P)-induced neoplasia of the forestomach than wild-type. Moreover, loss of Nrf2 abrogated the chemopreventive action of oltipraz, when administered 48 h before B[a]P, an interval allowing maximal induction of many phase 2 enzymes. Oltipraz also inhibits some cytochrome P450s involved in the bioactivation of B[a]P. In the present study we observed that oltipraz had no protective effect on tumor burden in the forestomach of nrf2-deficient mice when administered 1 h before B[a]P, a timeline that selectively optimizes for possible inhibitory effects on cytochrome P450s. To evaluate the role of nrf2 genotype on B[a]P disposition, levels of B[a]P–DNA adducts were measured as tetrols released from DNA isolated from target (forestomach) and non-target tissues (liver) of wild-type and nrf2-deficient mice treated with either vehicle or oltipraz 1 or 48 h before B[a]P. Levels of B[a]P–DNA adducts in forestomach were significantly higher in nrf2-deficient compared with wild-type mice. Oltipraz treatment at 1 or 48 h before B[a]P had no protective effect on forestomach tetrol levels in nrf2-deficient mice, whereas a significant reduction was observed in wild-type mice treated with oltipraz 48 h, but not 1 h, before carcinogen. Combining all treatments and genotypes, there was a strong correlation (R2 = 0.91) between levels of B[a]P–DNA adducts in forestomach and subsequent yield of tumors. In contrast to the results in forestomach, nrf2 genotype did not modify hepatic B[a]P–DNA adduct levels while both oltipraz treatments were protective, suggesting that Nrf2-independent mechanisms (e.g. P450 inhibition) for oltipraz can also occur in vivo in some tissues.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Loignon, W. Miao, L. Hu, A. Bier, T. A. Bismar, P. J. Scrivens, K. Mann, M. Basik, A. Bouchard, P. O. Fiset, et al. Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy Mol. Cancer Ther., August 1, 2009; 8(8): 2432 - 2440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang and R. Munday Dithiolethiones for cancer chemoprevention: where do we stand? Mol. Cancer Ther., November 1, 2008; 7(11): 3470 - 3479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Aoki, A. H. Hashimoto, K. Amanuma, M. Matsumoto, K. Hiyoshi, H. Takano, K.-i. Masumura, K. Itoh, T. Nohmi, and M. Yamamoto Enhanced Spontaneous and Benzo(a)pyrene-Induced Mutations in the Lung of Nrf2-Deficient gpt Delta Mice Cancer Res., June 15, 2007; 67(12): 5643 - 5648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Aleksunes and J. E. Manautou Emerging Role of Nrf2 in Protecting Against Hepatic and Gastrointestinal Disease Toxicol Pathol, June 1, 2007; 35(4): 459 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Umemura, Y. Kuroiwa, Y. Kitamura, Y. Ishii, K. Kanki, Y. Kodama, K. Itoh, M. Yamamoto, A. Nishikawa, and M. Hirose A Crucial Role of Nrf2 in In Vivo Defense against Oxidative Damage by an Environmental Pollutant, Pentachlorophenol Toxicol. Sci., March 1, 2006; 90(1): 111 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-J. Surh, J. K. Kundu, H.-K. Na, and J.-S. Lee Redox-Sensitive Transcription Factors as Prime Targets for Chemoprevention with Anti-Inflammatory and Antioxidative Phytochemicals J. Nutr., December 1, 2005; 135(12): 2993S - 3001S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Feng, Y. Lu, L. L. Bowman, Y. Qian, V. Castranova, and M. Ding Inhibition of Activator Protein-1, NF-{kappa}B, and MAPKs and Induction of Phase 2 Detoxifying Enzyme Activity by Chlorogenic Acid J. Biol. Chem., July 29, 2005; 280(30): 27888 - 27895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Lee, J. Li, D. A. Johnson, T. D. Stein, A. D. Kraft, M. J. Calkins, R. J. Jakel, and J. A. Johnson Nrf2, a multi-organ protector? FASEB J, July 1, 2005; 19(9): 1061 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Velichkova and T. Hasson Keap1 Regulates the Oxidation-Sensitive Shuttling of Nrf2 into and out of the Nucleus via a Crm1-Dependent Nuclear Export Mechanism Mol. Cell. Biol., June 1, 2005; 25(11): 4501 - 4513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Ki, I. J. Cho, D. W. Choi, and S. G. Kim Glucocorticoid Receptor (GR)-Associated SMRT Binding to C/EBP{beta} TAD and Nrf2 Neh4/5: Role of SMRT Recruited to GR in GSTA2 Gene Repression Mol. Cell. Biol., May 15, 2005; 25(10): 4150 - 4165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Calkins, R. J. Jakel, D. A. Johnson, K. Chan, Y. W. Kan, and J. A. Johnson Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription PNAS, January 4, 2005; 102(1): 244 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Iida, K. Itoh, Y. Kumagai, R. Oyasu, K. Hattori, K. Kawai, T. Shimazui, H. Akaza, and M. Yamamoto Nrf2 Is Essential for the Chemopreventive Efficacy of Oltipraz against Urinary Bladder Carcinogenesis Cancer Res., September 15, 2004; 64(18): 6424 - 6431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang and G. B. Gordon A strategy for cancer prevention: Stimulation of the Nrf2-ARE signaling pathway Mol. Cancer Ther., July 1, 2004; 3(7): 885 - 893. [Abstract] [Full Text] [PDF]
|
|